Vietnam Approves First Enterovirus A71 Vaccine as MVC and Substipharm Target Southeast Asian Expansion
核心洞察
Vietnam's Drug Administration has granted marketing authorization to ENVACGEN (搜索)®, marking the first-ever Enterovirus A71 vaccine approved in the country, addressing a critical pediatric health need.
The vaccine demonstrates exceptional clinical performance with 100% efficacy in trials and provides protection for infants as young as two months with immunogenicity lasting over five years.
MVC (搜索) and Substipharm Biologics (搜索) partnership aims to address Vietnam's significant disease burden, with 180,000 EV-A71 (搜索) cases and 31 deaths reported in 2023 alone.
Medigen Vaccine Biologics Corp (搜索). (MVC (搜索)) and Substipharm Biologics (搜索) have achieved a significant regulatory milestone with Vietnam's Drug Administration approving ENVACGEN (搜索)®, the country's first Enterovirus 71 (搜索) (EV-A71 (搜索)) vaccine. The approval represents a breakthrough in addressing a critical pediatric health crisis that has severely impacted Vietnam and the broader Southeast Asian region.
Addressing Critical Unmet Medical Need
Enterovirus 71 (搜索) stands as a primary cause of severe neurological complications and mortality in young children across Asia, with Vietnam experiencing particularly devastating impacts from cyclical outbreaks. In 2023 alone, Vietnam reported approximately 180,000 EV-A71 (搜索) cases and 31 deaths, highlighting the urgent need for effective prevention strategies. The disease burden has continued to escalate, with hand, foot and mouth disease (搜索) (HFMD (搜索)) cases increasing by 28.9% in 2025, reaching 107,249 reported cases.
These recurring health crises pose grave threats to pediatric populations and place heavy burdens on local healthcare systems throughout the region. The approval of ENVACGEN (搜索)® provides the first authorized vaccine solution specifically targeting this significant public health challenge in Vietnam.
Exceptional Clinical Performance Profile
ENVACGEN (搜索)® distinguishes itself as a "best-in-class" vaccine through its exceptional clinical performance metrics. The vaccine demonstrated 100% efficacy in clinical trials, with all confirmed cases occurring in the placebo group and achieving a statistical efficacy of 96.8% with a confidence interval of 85.5% to 100%.
The vaccine offers early protection for infants beginning at two months of age and provides long-term immunogenicity lasting over five years. This comprehensive protection profile addresses the vulnerable pediatric population most at risk for severe EV-A71 (搜索) complications.
Strategic Partnership for Regional Expansion
The collaboration between MVC (搜索) and Substipharm Biologics (搜索) builds upon MVC's established success in Taiwan, where ENVACGEN (搜索)® maintains a dominant market share exceeding 97%. Substipharm Biologics will spearhead marketing and distribution activities in Vietnam, leveraging their regional expertise and established presence across Southeast Asia.
With Vietnam's 1.36 million annual births representing substantial market potential, the partnership combines MVC (搜索)'s high-quality manufacturing capabilities with Substipharm's proven marketing expertise to rapidly address the region's significant unmet medical needs.
Leadership Perspectives on Market Impact
Leo Lee, CEO of MVC (搜索), emphasized the strategic importance of this regulatory achievement: "The successful marketing authorization of ENVACGEN (搜索)® as Vietnam's first EV71 vaccine is a pivotal milestone in MVC's global expansion. We are eager to work with our experienced partner, Substipharm Biologics (搜索), to provide this high-quality vaccine to local children."
Lee also highlighted MVC (搜索)'s commitment to meeting regional demand: "Facing the vast demand in Southeast Asia, MVC has already initiated capacity expansion plans to ensure a stable supply of premium vaccines."
Fabrice Baschiera, CEO of Substipharm Biologics (搜索), underscored the urgency of addressing the EV-A71 (搜索) threat: "With the recurrent, large-scale outbreaks of hand, foot and mouth disease (搜索) over the past decade, EV71 has long posed a severe challenge to pediatric health in Vietnam. We are thrilled to partner with MVC (搜索) to introduce this breakthrough, first-of-its-kind vaccine to the local market."
Company Capabilities and Track Record
MVC (搜索), established in 2012, operates as a leader in vaccine innovation with PIC/S GMP-certified facilities and maintains a diverse portfolio including enterovirus and influenza vaccines. During the COVID-19 pandemic, MVC distinguished itself as Taiwan's sole domestic vaccine manufacturer to receive Emergency Use Authorization.
Substipharm brings extensive international experience as a French pharmaceutical company distributing over 90 products across more than 100 countries. The company expanded into biologics with IMOJEV®, a Japanese encephalitis vaccine now available in 14 Asia-Pacific markets. Substipharm Biologics (搜索) operates facilities in Switzerland, Thailand, and Vietnam, reinforcing its regional presence and distribution capabilities.
The partnership positions both companies to establish a strong foundation for expanding their commercial footprint across Southeast Asia, addressing the region's critical need for effective EV-A71 (搜索) prevention strategies.